Cytex is delighted to be awarded entry to the highly successful Commercialization Acceleration Program offered as a competitive award to recipients of NIH Phase II SBIR or STTR awards. The program provides training and support for Cytex staff in commercialization activities such as regulatory planning, investment negotiations, and product marketing.
Cytex adds the most recent US patent granted, “Tissue Engineering Methods and Composition,” Division 2006287306 to its intellectual portfolio September 15, 2016.
Cytex is honored to have an image of its resurfacing scaffold selected for the cover image of the Spring-Summer 2016 edition of Science Editor.
Cytex’s technology appeared in a National Institutes of Health article published August 9, 2016 discussing stem cells grown on a scaffold to mimic hip joint cartilage. The article concluded the findings could lead to new approaches in treating injury or joint surface damage by osteoarthritis. The research cited was supported by multiple grants from NIH’s […]
Cytex’s intellectual portfolio continues to strengthen with the latest patent issued, “Tissue Engineering Methods and Composition,” in Canada on June 21, 2016.
Cytex’s technology, as published in the latest Proceedings of the National Academy of Sciences, is making a splash worldwide. Cytex’s scientists and cartilage resurfacing technology was featured in U.S. News and World Report Health News, The Huffington Post, Health, Yahoo News, and dozens of other news outlets in response to the recently published study in […]
Cytex’s VP of Research and Development, Dr. Brad Estes and Dr. Farsh Guilak, Professor of Orthopaedic Surgery at Washington University and Cytex’s President, co-led a team of researchers in a study published July 18, 2016 in the prestigious journal PNAS. Results from this study highlighted Cytex’s tissue engineered implants’ cartilage-like properties, ability to maintain complex […]
The ORS hosts the premier orthopaedic research conference for basic science and clinical researchers in the United States. Dr. Moutos presented findings from cutting-edge research in a talk entitled “Anatomically Shaped Tissue-Engineered Cartilage with Tunable and Inducible Anti-Cytokine Delivery for Biological Joint Resurfacing.”
Cytex is thrilled to add the expertise of Dr. Vincent P. Willard to our talented team. Dr. Willard brings over 14 years of research experience in molecular and stem cell biology, orthopaedic tissue engineering, and gene therapy to Cytex. He will serve as the Director of Regenerative Therapies.
Cytex is grateful for the support of the State of North Carolina. Cytex has been awarded a matching grant to compliment the work being achieved through its recently awarded federal SBIR Grant entitled Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model.